Skin and Nail Responses after 1 Year of Infliximab Therapy in Patients with Moderate-to-Severe Psoriasis: A Retrospective Analysis of the EXPRESS Trial

Publisher： Karger

E-ISSN： 1421-9832|221|2|172-178

ISSN： 1018-8665

Source： Dermatology, Vol.221, Iss.2, 2010-07, pp. : 172-178

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Patients with Moderate to Severe Plaque Psoriasis: One Year after the European Medicines Agency Recommendation of Efalizumab Suspension

By  

Dermatology, Vol. 222, Iss. 3, 2011-04 ,pp. : 250-255

Karger

Access to resources Recommend Favorite

Real-World Outcome Analysis of Continuously and Intermittently Treated Patients with Moderate to Severe Psoriasis after Switching to a Biologic Agent

By  

Dermatology, Vol. 230, Iss. 4, 2015-02 ,pp. : 347-353

Karger

Access to resources Recommend Favorite

Once-Weekly Administration of Etanercept 50 mg Improves Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis

By  

Dermatology, Vol. 219, Iss. 3, 2009-09 ,pp. : 239-249

Karger

Access to resources Recommend Favorite

Relationship between Clinical Response to Therapy and Health-Related Quality of Life Outcomes in Patients with Moderate to Severe Plaque Psoriasis

By  

Dermatology, Vol. 216, Iss. 3, 2008-01 ,pp. : 260-270

Karger

Access to resources Recommend Favorite

Response of Severe Psoriasis to Infliximab

By  

Dermatology, Vol. 204, Iss. 2, 2002-04 ,pp. : 156-157

Karger

Access to resources Recommend Favorite